Megan Chambers, MD
Ophthalmology · Columbus, OHNPI 1154632198
Payments from drug & device makers
Across 139 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$411
- AbbVie$343
- Aerie Pharmaceuticals, Inc.$309
- NEW World Medical,inc.$260
- Bausch & Lomb Americas Inc.$254
- Biotissue Holdings Inc.$185
- plus $1K from 21 others
What the payments were for
- Food & beverage$2,77394%
- Education$1886%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 17 | $411 |
| AbbVie(2 entities) | 20 | $343 |
| Aerie Pharmaceuticals, Inc. | 9 | $309 |
| NEW World Medical,inc. | 7 | $260 |
| Bausch & Lomb Americas Inc. | 13 | $254 |
| Biotissue Holdings Inc. | 9 | $185 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $181 |
| Dompe US, Inc. | 7 | $152 |
| Glaukos Corporation | 4 | $116 |
| Novartis | 6 | $111 |
| Sun Pharmaceutical Industries Inc. | 4 | $93 |
| Amgen | 5 | $76 |
| Kala Pharmaceuticals, Inc. | 5 | $70 |
| Mallinckrodt Hospital Products Inc. | 4 | $66 |
| Oyster Point Pharma, Inc. | 3 | $50 |
| Harrow Eye, LLC | 2 | $39 |
| Sight Sciences, Inc. | 2 | $36 |
| Tarsus Pharmaceuticals, Inc. | 1 | $36 |
| ANI Pharmaceuticals, Inc. | 1 | $30 |
| Ocular Therapeutix, Inc. | 2 | $26 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $22 |
| Tearlab Corp | 1 | $20 |
| Rxsight Inc | 1 | $20 |
| Ivantis, Inc | 1 | $17 |
| Thea Pharma Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $11 |
| Merz Pharmaceuticals, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kahook Dual Blade$135
- Clearpath$135
- Ahmed Glaucoma Valve$135
- Streamline$135
- AcrySof IQ VIVITY IOL$112
How this compares
$2,961 in reported general payments places this provider in the 70th percentile of 640 ophthalmology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RocklatanNetarsudil Mesylat/Latanoprost | 111 | $62,433 |
| RestasisCyclosporine | 58 | $50,862 |
| LumiganBimatoprost | 93 | $45,512 |
| XiidraLifitegrast | 32 | $40,734 |
| VyzultaLatanoprostene Bunod | 63 | $30,268 |
| CombiganBrimonidine Tartrate/Timolol | 82 | $25,976 |
| RhopressaNetarsudil Mesylate | 48 | $21,810 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 73 | $20,140 |
| Prednisolone Acetate | 389 | $9,083 |
| Alphagan PBrimonidine Tartrate | 30 | $8,397 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 62 | $7,137 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 396 | $6,652 |
| Latanoprost | 619 | $5,556 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 43 | $5,323 |
| Travoprost | 15 | $4,903 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $343 | $130,746263 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $309 | $84,242159 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $254 | $71,00295 claims |
| AlconSimbrinza | $411 | $20,14073 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 640 ophthalmology providers in Ohio.
Other ophthalmology in Columbus
- David RogersColumbus$1.5M
- Alice EpitropoulosColumbus$702K
- Steven KatzColumbus$256K
- David LehmannColumbus$58K
- Lisa BorkowskiColumbus$25K
- John PajkaLima$17.7M
- Justis EhlersCleveland$5M
- Lawrence SingermanBeachwood$3.9M
- Sunil SrivastavaCleveland$2.8M
- Daniel MillerCincinnati$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.